Prometheus Biosciences, Inc.

NasdaqGS:RXDX Stock Report

Market Cap: US$9.6b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Prometheus Biosciences Management

Management criteria checks 1/4

Prometheus Biosciences' CEO is Mark McKenna, appointed in Sep 2019, he has a tenure of 3.75 years. His total yearly compensation is $19.94M , comprised of 3% salary and 97% bonuses, including company stock and options. He directly owns 0.29% of the company’s shares, worth $28.17M. The average tenure of the management team and the board of directors is 2.5 years and 2.3 years respectively.

Key information

Mark McKenna

Chief executive officer

US$19.9m

Total compensation

CEO salary percentage2.97%
CEO tenure3.8yrs
CEO ownership0.3%
Management average tenure2.5yrs
Board average tenure2.3yrs

Recent management updates

Recent updates

Seeking Alpha • Aug 11

Prometheus Biosciences GAAP EPS of -$0.86 beats by $0.06, revenue of $1.26M beats by $0.8M

Prometheus Biosciences press release (NASDAQ:RXDX): Q2 GAAP EPS of -$0.86 beats by $0.06. Revenue of $1.26M (+320.0% Y/Y) beats by $0.8M.
Seeking Alpha • Dec 08

Prometheus: Biotech To Watch With A Monoclonal Antibody For Immune-Mediated Diseases

Prometheus displays positive phase 1 safety data with PRA023. Drug also shows target engagement with mode of action in healthy volunteers. Based on the phase 1 data, biotech has added a 3rd indication for PRA023, which is Systemic Sclerosis-Associated Lung disease. Phase 1 study to start Q1 of 2022. Phase 2 results using PRA023 for both Ulcerative Colitis and Crohn's Disease are expected to be released in Q4 of 2022. An IND submission using another monoclonal antibody from the TNF superfamily, known as PR600, is expected in Q3 of 2022.
Seeking Alpha • Sep 22

Prometheus Biosciences: Precision Medicine For IBD

Prometheus has built the leading platform and data set for IBD drug development that has enabled partnerships, a diverse pipeline, and non-dilutive capital. IBD is a market opportunity representing millions of patients, which has had little innovation over the last 2 decades. The company has an upcoming catalyst with Phase 1 data coming out for their lead asset over the next few months, which can set up a Phase 2 clinical trial.

CEO Compensation Analysis

How has Mark McKenna's remuneration changed compared to Prometheus Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2023n/an/a

-US$151m

Dec 31 2022US$20mUS$592k

-US$142m

Sep 30 2022n/an/a

-US$133m

Jun 30 2022n/an/a

-US$123m

Mar 31 2022n/an/a

-US$108m

Dec 31 2021US$12mUS$566k

-US$90m

Sep 30 2021n/an/a

-US$69m

Jun 30 2021n/an/a

-US$50m

Mar 31 2021n/an/a

-US$38m

Dec 31 2020US$3mUS$500k

-US$31m

Dec 31 2019US$976kUS$157k

-US$17m

Compensation vs Market: Mark's total compensation ($USD19.94M) is above average for companies of similar size in the US market ($USD8.17M).

Compensation vs Earnings: Mark's compensation has increased whilst the company is unprofitable.

CEO

Mark McKenna (43 yo)

3.8yrs
Tenure
US$19,936,088
Compensation

Mr. Mark C. Mckenna serves as President, Chief Executive Officer, Chairman of the Board at Prometheus Biosciences, Inc. since August 2021. He serves as Director of Rebalance Health, Inc. He serves as Execu...

Leadership Team

NamePositionTenureCompensationOwnership
Mark McKenna
President3.8yrsUS$19.94m0.29%
$ 28.2m
Keith Marshall
Chief Financial Officer2.8yrsUS$7.12m0.18%
$ 17.6m
Mark Stenhouse
Chief Operating Officer2.3yrsUS$6.16m0.035%
$ 3.4m
Olivier Laurent
Chief Scientific Officer & Head of R&D1.5yrsno datano data
Noel Kurdi
Vice President of Investor Relations & Communicationsno datano datano data
Timothy Andrews
General Counsel & Secretary2.6yrsno datano data
Nori Ebersole
Chief People Officer2.2yrsno datano data
Allison Luo
Chief Medical Officer4.8yrsUS$4.24m0%
$ 0
Thierry Dervieux
Chief Development Officer of Diagnostics & Medical Laboratory Director3.5yrsno datano data
Chris Doughty
Chief Business Officer2.4yrsno datano data
Evan McClure
Chief of Staff & VP of Business Operations2.4yrsno datano data
Vika Brough
Senior Vice President of Financeno datano datano data
2.5yrs
Average Tenure
53yo
Average Age

Experienced Management: RXDX's management team is considered experienced (2.5 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Mark McKenna
President3.8yrsUS$19.94m0.29%
$ 28.2m
Fred Hassan
Independent Director2.1yrsUS$441.91k0%
$ 0
Joseph Papa
Lead Independent Director2.8yrsUS$463.28k0.031%
$ 3.0m
Mary Szela
Independent Director2.3yrsUS$442.29k0%
$ 0
Judith Swain
Independent Director2.3yrsUS$429.79k0%
$ 0
Helen Adams
Independent Director2.3yrsUS$444.04k0.0010%
$ 100.4k
Bruce Sands
Chairman of Scientific Advisory Board1.1yrsno datano data
Stephan Targan
Member of Scientific Advisory Boardno datano datano data
Martin Hendrix
Independent Director2.7yrsUS$439.79k0%
$ 0
James Laur
Director3.2yrsUS$424.79k0%
$ 0
Dermot McGovern
Member of Scientific Advisory Boardno datano datano data
Donna Griebel
Member of Scientific Advisory Boardno datano datano data
2.3yrs
Average Tenure
62.5yo
Average Age

Experienced Board: RXDX's board of directors are not considered experienced ( 2.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2023/06/17 00:46
End of Day Share Price 2023/06/15 00:00
Earnings2023/03/31
Annual Earnings2022/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Prometheus Biosciences, Inc. is covered by 11 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hiroshi ShibutaniGoldman Sachs
Yatin SunejaGuggenheim Securities, LLC
Christopher HowertonJefferies LLC